11年PCV 疫苗研究首次补足国内证据链：高致病血清型减少，为公共卫生添 “硬核” 依据

Core Insights - A long-term real-world study conducted over 11 years confirms that the pneumococcal conjugate vaccine (PCV) effectively prevents pneumococcal diseases and significantly reduces antibiotic resistance [1][2] - The study fills a critical evidence gap regarding the long-term public health impact of PCV13 in China, providing essential data for optimizing immunization strategies [1] Summary by Sections Vaccine Efficacy - The study found that the serotypes covered by PCV13 accounted for 96.8% of invasive isolates, indicating its effectiveness against major pathogenic types in China [2] - The proportion of vaccine-covered serotypes in overall pneumococcal diseases decreased significantly from 92.8% to 59.2%, demonstrating a clear downward trend and the protective effect of the vaccine [2] - Notably, the highly resistant serotype 19F dropped from 59.2% to 14.4%, leading to a reduction in the non-sensitivity rate of beta-lactam antibiotics from 16.0% to 2.4% [2] Public Health Implications - The research highlights the public health value of PCV vaccination in reducing the transmission of highly pathogenic and resistant serotypes, proving it to be a powerful tool against invasive pneumococcal disease (IPD) and antibiotic resistance [2] - The study serves as a "real-world report card," providing scientific evidence for vaccine strategies while addressing the limitations of traditional clinical trials [2] Global Context and Challenges - Pfizer's experience with PCV vaccines globally shows that over 300 million children have been protected from IPD, with significant reductions in IPD incidence reported in various countries [4] - In China, the burden of pneumococcal disease in children under five is severe, with over 560,000 cases annually and approximately 8,000 deaths [4] Vaccination Coverage and Future Directions - There is a significant gap in PCV vaccination rates in China, with an estimated coverage of only 7.3% compared to the global average of 47.9% in 2019 [5] - Continuous monitoring and iterative research and development are essential to address the evolving challenges posed by changing serotype distributions and to enhance vaccine efficacy [5] Technological Innovations - Pfizer emphasizes the importance of ongoing innovation in vaccine development, highlighting the transition from PCV7 and PCV13 to higher-valent vaccines like PCV20, which address complex technical challenges [5] - The use of CRM197 as a carrier protein in higher-valent vaccines has proven to be scientifically sound and advantageous, aiming to provide comprehensive protection against pneumococcal diseases [5]